These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Interaction between alpha- and beta-adrenoceptor-mediated cardiovascular effects.
    Author: van Zwieten PA.
    Journal: J Cardiovasc Pharmacol; 1986; 8 Suppl 4():S21-8. PubMed ID: 2427848.
    Abstract:
    A survey is given of the mutual interaction of alpha- and beta-adrenoceptor mediated cardiovascular effects, with an emphasis on the effects of drugs which simultaneously block alpha- and beta-adrenoceptors. This discussion is preceded by a review of the various subtypes of adrenoceptors, including pre/postsynaptic, alpha 1/alpha 2- and beta 1/beta 2-receptors with an emphasis on their various selective agonists and antagonists and their functional aspects. For drugs which display comparable degrees of alpha- and beta-adrenoceptor blockade the following effects may be anticipated: vasodilatation, a reduction in total peripheral resistance (TPR) and a decrease in blood pressure, as a result of postsynaptic (alpha 1 + alpha 2) adrenoceptor blockade; a fall in blood pressure as a result of beta-receptor blockade; no reflex tachycardia in spite of the vasodilatation (alpha 1 + alpha 2 blockade) owing to beta-receptor blockade. For a drug which simultaneously blocks alpha 2- and beta 1-adrenoceptors the following effects may be anticipated: all cardiac changes usually induced by beta 1-blockade (reduced heart rate, contractility and A-V conduction); vasodilatation induced by postsynaptic alpha 2-adrenoceptor blockade; enhanced release of presynaptic noradrenaline, owing to presynaptic alpha 2-receptor blockade. Celiprolol is an example of a drug which combines alpha 2- and beta 1-adrenoceptor blocking properties. It should be realized, however, that the alpha 2-receptor affinity of the drug is much lower than its beta 1-receptor antagonism, which probably dominates the drug's profile.
    [Abstract] [Full Text] [Related] [New Search]